Fallout From This Heart-Drug Failure

Big biotech Amgen and its partner Cytokinetics had an intriguing drug candidate -- omecamtiv mecarbill, which treats shortness of breath in patients with acute heart failure -- fail a mid-stage trial. Amgen wasn't affected, but shares of Cytokinetics plunged 25% on the news.

There is a caveat to this failure: It was at the lower dosing, and most analysts didn't expect the trial to succeed. The higher dosing did show efficacy, but when the data was pooled, the results became muddled.

In this video, health-care analyst David Williamson discusses whether the heart-failure drug will reach phase 3 testing and looks at whether Cytokinetics or Amgen is the better play for investors.

Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2637800, ~/Articles/ArticleHandler.aspx, 4/20/2014 3:31:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement